ISPOR Europe

Share on:

Sunday, November 9 - Wednesday, November 12, 2025

Scotland
Glasgow
G1 3QX
United Kingdom

We are pleased to be a year-round sponsor of ISPOR. Our team will also be attending, speaking, and presenting in Glasgow. Take a look at our schedule below and meet us at booth #607.

Scroll down to see what we're bringing to ISPOR and who will be attending.

Short Courses | Sunday 9 November

1:00 - 5:00 PM GMT

009

Budget impact analysis II: practical steps to building a BIA and enhanced applications. Earnshaw S, Brogan A, Brodtkorb TH, Davis A.

Location: Dochart

8:00 - 12:00 PM GMT

002

Advanced patient-reported outcomes. Crawford R, Qin S, Doward L, Rockwood NJ.

Location: Boisdale

Presentations & Sessions | Monday 10 November

10:15 - 11:15 AM GMT

013

Patient preference evidence in health technology assessment: what do we really know? Hauber B, Watson V, Meads D, Germeni E.

Location: Alsh

1:45 - 2:45 PM GMT

036

How could patient-centric HTA evolve in the changing global pricing landscape? Sullivan SD, Wu O, Doward L, Adlard N.

Location: Hall 2

3:15 - 3:45 PM GMT

Theater

EU Joint Clinical Assessment for Orphan Drugs: Methodological Challenges, Solutions, and Early Learnings

Location: Exhibit Hall Theater 1

Presentations & Sessions | Tuesday 11 November

8:00 - 9:00 GMT

Issue Panel 127

The Variable Thresholds Issue: A Necessary Tool or a Misguided Obsession?
Moderator: Postma M
Speakers: Caro JJ, van Asselt T, Herring WL

Quality of life and utility values across the Alzheimer's disease spectrum: results from the What Matters Most survey. Herring WL, Romano (DeMuro) C, Houghton K, Dardis G, McLeod L, Paulsen R.

The value of the health and wellbeing benefits of healthcare facilities outdoor spaces. Loria-Rebolledo L, Chalmers N, Watson V, Boyers D, Antunes M.

Poster Session I | Monday 10 November

10:30 AM - 1:30 PM GMT

HTA172

Health technologies using artificial intelligence: what is being assessed in the UK by NICE? Leonard C, Warttig S, Gildea L.

Poster board number: 3039

10:30 AM - 1:30 PM GMT

PCR18

Are discrete choice experiment results robust to omitted attributes? Evidence from a vaccine study. Genie M, Watson V, Luchini S, Schwarzinger M.

Poster board number: 3130

Poster Session 2 | Monday 10 November

4:00 - 7:00 PM GMT

HSD90

Potential operational efficiencies of a combination influenza and COVID-19 vaccine in US pharmacies. Sweeney C, Boyle K, Calhoun S, Davenport E, Wang WJ, Mehta D.

Poster Board Number: 2140

4:00 - 7:00 PM GMT

PCR59

Development of a discrete choice experiment survey to assess patient preferences for treatment of metastatic breast cancer. Chandiwana D, Rose CG, Benjumea D, Coulter J, Schroeder N, Vass C, Bussberg C, Karim S, Watson V, Edwards M.

Poster board number: 3113

Poster Session 3 | Tuesday 11 November

10:30 AM - 1:30 PM GMT

MT26

HTA requirements for medical technologies in Germany. Leonard C, Warttig S, Gildea L, Mordin M.

Poster board number: 3029

10:30 AM - 1:30 PM GMT

EE429

Estimation of utility weights for patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukaemia (CLL) previously treated with a covalent BruTon Kinase inhibitor (cBTKi). Masoudi E, Jen MH, Graham CN, Erbe A, Maguire PT, Taipale KL, Qiao C, Zhang Z, Han Y, Graham-Clarke PL.

Poster board number: 1108

10:30 AM - 1:30 PM GMT

HTA182

How will patient registry data play a role in joint clinical assessment JCA for rare diseases? Llearnings from national health technology assessments HTAs. Hartley L, Wolowacz S, Ling C.

Poster board number: 2157

Poster Session 4 | Tuesday 11 November

4:00 - 7:00 PM GMT

EPH220

Studying paternal drug exposures and offspring outcomes: a feasibility assessment of 11 large European databases. Colas S, Bonnet H, Fraticelli L, Bignon E, Jove J, Ehrenstein V, Giner-Soriano M, Reinold J, Schafer W, Tolppanen AM, Cesta C, Cohen J, Pajouheshnia R, Kuiper J, Houben E, Kurzinger ML, Longin J, Carcaillon-Bentata L.

Poster board number: 2022

Poster Session 5 | Wednesday 12 November

9:00 - 11:30 AM GMT

HTA315

The elusive PICO: assessing prediction in joint clinical assessments (JCA): a case study in soft tissue sarcoma (STS). D'Souza V, Njue A, Hartley L, Singh K, Mueller M, Hopkinson PK, Ling C.

Poster board number: 2132

9:00 - 11:30 AM GMT

EPH234

The estimation of the prevalent presymptomatic type 1 diabetes population in Germany using a patient funnel model. Mahieu A, Omar Alsaleh AJ, Clemmet T, Basarir H, Azabdaftari D, Bornholdt K, Hergl M, Ziegler AG.

Poster board number: 2027

9:00 - 11:30 AM GMT

HPR236